E Fund CSI Innovative Drugs ETF (516080) rises 1.53%, aiming for a third consecutive gain

NewTimeSpace News, as of 13:33 on June 23, 2026, E Fund Innovative Drug ETF (516080) rose 1.53%, aiming for a third consecutive gain. The latest price was 0.60 yuan. Over a longer time frame, as of June 22, 2026, the ETF accumulated a gain of 1.38% over the past week.

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 6.5% and a trading volume of 115 million yuan. Over a longer time frame, as of June 22, the ETF's average daily trading volume over the past week reached 71.2097 million yuan, ranking in the top 3 among comparable funds.

In terms of scale, the latest scale of E Fund Innovative Drug ETF reached 1.727 billion yuan, hitting a one-year high and ranking 3/7 among comparable funds. (Data source: Wind)

In terms of shares, E Fund Innovative Drug ETF experienced a significant increase of 45.00 million units in share count over the past week, with the new share increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for E Fund Innovative Drug ETF was 26.9947 million yuan. Over a longer time frame, within the past four trading days, it attracted a total of 25.8716 million yuan in net inflow. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. E Fund Innovative Drug ETF has seen net purchases by leveraged funds for three consecutive days, with the highest single-day net purchase reaching 5.0696 million yuan. The latest margin financing balance stood at 40.2699 million yuan. (Data source: Wind)

As of June 22, the net value of E Fund Innovative Drug ETF rose by 21.90% over the past two years, ranking first among comparable funds. From the perspective of return capability, as of June 22, 2026, since its inception, the ETF achieved a highest single-month return of 22.96%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 33.43%, and an average return of 5.62% in up months. As of June 22, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.76%, ranking in the top 2/7 among comparable funds.

In terms of drawdown, as of June 22, 2026, E Fund Innovative Drug ETF recorded a drawdown of 0.16% relative to its benchmark since the beginning of the year.

In terms of fees, E Fund Innovative Drug ETF has a management fee rate of 0.15% and a custodian fee rate of 0.05%, the lowest fee rates among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which E Fund Innovative Drug ETF tracks, is only 42.41 times, standing at the 8.71% percentile over the past year. This means the valuation is lower than over 91.29% of the time in the past year, placing it at a historical low.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.